Oncternal Therapeutics Inc. CVRPreferred / convertible
13F holders, Q4 2024 (December 31)1holders
0new positions
0sold out
$0.00avg. 13F price*
At the end of Q4 2024, 1 institutions reported holding Oncternal Therapeutics Inc. CVR in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holder was Rhumbline Advisers ($0).
- Company
- Oncternal Therapeutics Inc. CVR
- CUSIP
- 400CVR015
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Rhumbline Advisers | — | No change | 101 | $0 |
"% of holder's portfolio" is ONCTERNAL THERAPEUTICS INC CVR's weight in each manager's 13F, not the share of Oncternal Therapeutics Inc. CVR the manager owns.